electroCore, Inc. (ECOR)
| Market Cap | 72.81M |
| Revenue (ttm) | 3.50M |
| Net Income (ttm) | -23.51M |
| Shares Out | 39.00M |
| EPS (ttm) | -0.60 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | May 7 |
| Last Price | $1.50 |
| Previous Close | $1.53 |
| Change ($) | -0.03 |
| Change (%) | -1.96% |
| Day's Open | 1.52 |
| Day's Range | 1.46 - 1.63 |
| Day's Volume | 878,248 |
| 52-Week Range | 0.77 - 3.63 |
Record First quarter 2021 net sales of $1.2 million, increased 64% over first quarter 2020 and 30% sequentially
ROCKAWAY, NJ, April 29, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (NASDAQ: ECOR), a commercial-stage bioelectronic medicine company, announced that it will report financial results for the first quarte...
ROCKAWAY, NJ, April 26, 2021 (GLOBE NEWSWIRE) -- -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Johns Hopkins University School of Medicine...
ROCKAWAY, NJ, April 15, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Cluster heada...
ROCKAWAY, NJ, April 13, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today provided an operating and business update as well as select u...
ElectroCore Inc (NASDAQ: ECOR) has announced top-line results from the SAVIOR-1 study evaluating non-invasive vagus nerve stimulation (nVNS) using gammaCore Sapphire in hospitalized COVID-19 patients. T...
nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of treatment nVNS decreases certain biomarkers associated with the severity of COVID-19 through five days of ...
ElectroCore's Stock Is Trading Higher After Its Nerve Stimulator Wins Canadian Approval For Migraine
Health Canada has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products to prevent and treat migraine and cluster headache. GammaCore Sapphire will be distributed in Canada by ...
ROCKAWAY, NJ, April 05, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that Health Canada has granted regulatory approval f...
ROCKAWAY, N.J.--(BUSINESS WIRE)--Amid the vaccine roll out, 97,309 new cases of COVID-19 have been reported to the CDC. Peter Staats, M.D. Chief Medical Officer of electroCore, Inc. (Nasdaq: ECOR), outl...
Full year 2020 net sales of approximately $3.5 million increased 46% over $2.4 million for full year 2019
ROCKAWAY, N.J., March 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in two upcoming i...
Shares of electroCore, Inc. (NASDAQ: ECOR) were trading higher Monday following the company's announcement of an exclusive distribution agreement with Medistar following regulatory approval in Australia...
ElectroCore (ECOR) stock is rocketing higher on Monday after announcing a distribution deal in Australia for its gammaCore Sapphire. The post ECOR Stock: The Deal That Has Medical Device Company Electro...
The Australian Therapeutic Goods Administration has approved ElectroCore Inc's (NASDAQ: ECOR) gammaCore Sapphire family of products, including a non-invasive vagus nerve stimulator (nVNS) for primary he...
ROCKAWAY, N.J., Feb. 28, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Medistar...
ElectroCore Inc (NASDAQ: ECOR) and the Hospital Clínico Universitario de Valencia in Spain have completed the enrollment in the SAVIOR-1 study. This study was supported in part by electroCore.
ROCKAWAY, N.J.--(BUSINESS WIRE)--electroCore,Inc.(Nasdaq: ECOR) closes patient enrollment study SAVIOR-1 to better understand clinical benefit of non-invasive vagus nerve stimulation
Extension maintains listing through June 3, 2023 Extension maintains listing through June 3, 2023
FDA clearance expands gammaCore label to include the acute and preventive treatment of migraine in adolescents 12 to 17 years of age FDA clearance expands gammaCore label to include the acute and preven...
ROCKAWAY, N.J., Feb. 09, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a peer reviewed paper, entitled:...
ROCKAWAY, N.J., Feb. 03, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management will participate in a fireside chat...
ROCKAWAY, N.J., Feb. 02, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that full enrollment has been achieved for the TR-V...
ROCKAWAY, N.J., Jan. 26, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with RSK Medi...
ROCKAWAY, N.J., Jan. 21, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Health Improvement Scotland (“HIS”) has publis...
ROCKAWAY, N.J., Jan. 19, 2021 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Centers for Medicare and Medicaid Services (“C...
Full year 2020 revenue expected at the upper end of previously announced guidance range of $3.3M - $3.5M; greater than 40% growth over full year 2019 revenue of $2.4M
ROCKAWAY, N.J., Dec. 21, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that it has entered into an agreement with Pro Medi...
BASKING RIDGE, N.J., Dec. 07, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today that management is scheduled to present at the...
electroCore's (ECOR) CEO Dan Goldberger on Q3 2020 Results - Earnings Call Transcript
Shares of electroCore (NASDAQ:ECOR) moved higher by 10.83% in after-market trading after the company reported Q3 results. Quarterly Results Earnings per share were up 71.43% over the past year to ($0.10...
On Thursday, November 12, electroCore (NASDAQ: ECOR) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Conference Call to be Held at 4:30pm Eastern Time Conference Call to be Held at 4:30pm Eastern Time
Third quarter 2020 Revenue expected to exceed $1 million , representing an increase of greater than 35% sequentially and greater than 50% over Q3 2019
ITP program providing reimbursement for gammaCore ™ extended to March. 31, 2021 with option for additional three years
BASKING RIDGE, N.J., Sept. 30, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that the Department of Veterans Affairs has a...
Comprehensive telehealth platform to facilitate the efficient procurement of gammaCore Sapphire™ CV (non-invasive vagus nerve stimulator) by known or suspected COVID-19 patients Comprehensive telehealth...
BASKING RIDGE, N.J., Sept. 23, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that Dan Goldberger, chief executive office...
BASKING RIDGE, N.J., Sept. 11, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced that management is scheduled to present at ...
BASKING RIDGE, N.J., Aug. 27, 2020 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, today announced the publication of a paper, entitled, “Non-i...
Reimbursement for gammaCore™ in England Reimbursement for gammaCore™ in England
Rock-solid financial stats and a highly specific medical technology add up to a compelling argument in favor of ECOR stock. The post Make ElectroCore a Core Holding after an Outstanding Q2 appeared firs...
electroCore, Inc's (ECOR) CEO Dan Goldberger on Q2 2020 Results - Earnings Call Transcript
Shares of electroCore (NASDAQ:ECOR) fell 3.1% in after-market trading after the company reported Q2 results.
Received EUA and initiated gammaCore Sapphire CV distribution process for certain known or suspected COVID-19 patients experiencing asthma exacerbations
Conference Call to be Held at 4:30pm Eastern Time Conference Call to be Held at 4:30pm Eastern Time
Whether it’s all speculation or day trading, it seems there is no end to seeing major gains in small and micro-cap stocks that have positive announcements around anything to do with testing, vaccines, t...
Initial distribution to hospitals and patients expected to begin on July 31st Initial distribution to hospitals and patients expected to begin on July 31st
Bioelectronic medicine's crucial role has come into focus with Covid-19, and a recent FDA approval practically assures ECOR stock's ascent. The post FDA Green Light Makes ElectroCore a Micro-Cap to Wat...
Paper supports use of nVNS as a front-line therapy for acute and preventative treatment of cluster headache and as an effective option for the treatment of migraine headache Paper supports use of nVNS a...
About ECOR
electroCore, Inc., a commercial stage medical device company, engages in the development and commercialization of a range of non-invasive vagus nerve stimulation (nVNS) therapies. The company is developing gammaCore, a prescription-only nVNS therapy for the acute treatment of pain associated with migraine and episodic cluster headache in adults. Its lead product is gammaCore Sapphire, a rechargeable and reloadable handheld delivery system for multi-year use prescribed on a monthly basis. The company was founded in 2005 and is headquartered in R... [Read more...]
| Industry Medical Instruments & Supplies | IPO Date Jun 22, 2018 |
| CEO Francis Amato | Employees 45 |
| Stock Exchange NASDAQ | Ticker Symbol ECOR |
Financial Performance
In 2020, electroCore's revenue was $3.50 million, an increase of 46.25% compared to the previous year's $2.39 million. Losses were -$23.51 million, -47.92% less than in 2019.
Analyst Forecasts
According to 5 analysts, the average rating for electroCore stock is "Buy." The 12-month stock price forecast is 3.70, which is an increase of 146.67% from the latest price.